956821-91-3Relevant academic research and scientific papers
MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY
-
Page/Page column 83, (2010/06/17)
Provided herein are Heteroaryl Compounds having the following structure: R2 N (I) or (II) wherein R1 -R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS
-
Page/Page column 67, (2010/04/30)
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein W1, W2, W3, R1/s
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3- (6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl) pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kin
Velaparthi, Upender,Wittman, Mark,Liu, Peiying,Carboni, Joan M.,Lee, Francis Y.,Attar, Ricardo,Balimane, Praveen,Clarke, Wendy,Sinz, Michael W.,Hurlburt, Warren,Patel, Karishma,Discenza, Lorell,Kim, Sean,Gottardis, Marco,Greer, Ann,Li, Aixin,Saulnier, Mark,Yang, Zheng,Zimmermann, Kurt,Trainor, George,Vyas, Dolatrai
supporting information; experimental part, p. 5897 - 5900 (2009/10/09)
We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity. This lead compound was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PX
Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR)
Hubbard, Robert D.,Bamaung, Nwe Y.,Palazzo, Fabio,Zhang, Qian,Kovar, Peter,Osterling, Donald J.,Hu, Xiaoming,Wilsbacher, Julie L.,Johnson, Eric F.,Bouska, Jennifer,Wang, Jieyi,Bell, Randy L.,Davidsen, Steven K.,Sheppard, George S.
, p. 5406 - 5409 (2008/03/13)
A high throughput screen of Abbott's compound repository revealed that the pyrazolo[3,4-d]pyrimidine class of kinase inhibitors possessed moderate potency for IGF-IR, a promising target for cancer chemotherapy. The synthesis and subsequent optimization of this class of compounds led to the discovery of 14, a compound that possesses in vivo IGF-IR inhibitory activity.
HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES
-
Page/Page column 20, (2010/11/24)
A compound of formula I, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or solvate thereof, methods of using such compounds in the treatment of hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases; and to pharmaceutical compositions containing such compounds
